Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Furosemide and Spironolactone by Vierordt’s Method in Bulk and Combined Tablet Dosage Form

Abstract

Anew simple, convenient and suitable spectrophotometric method for simultaneous determination of Furosemide and Spironolactone in combined dosage form has been developed and validated. Simultaneous equation method (Vierordt’s method) was used for determination of Furosemide and Spironolactone in combined dosage form. For spectrophotometric method development double distilled water and ethanol were used as a solvent in the ratio of (20:80). The proposed method was quantitatively evaluated in terms of linearity, precision, accuracy, lower limit of detection (LOD) and quantification (LOQ), recovery and robustness. All the parameters were found to be within the acceptance limit. λmax of Furosemide and Spironolactone was found to be 275 and 237 nm respectively. Beer’s law was obeyed over the concentration ranges of 2-10 μg mL−1 for both Furosemide and Spironolactone respectively. The % assay for commercial formulation was found to be 99.60%±0.0500 for Furosemide and 100.26%±1.17 for Spironolactone by the proposed methods. The overall recovery was observed to be 100.38±0.09% for Furosemide and 100.49±0.4197% for Spironolactone by simultaneous equation method (Vierordt’s method). LOD and LOQ were 0.76 and 2.32 μg mL−1 for Furosemide, 1.99 and 6.04 μg mL−1 for Spironolactone. A new simple, convenient, precise, rapid, accurate and economical and reliable spectrophotometric method was developed and validated for the analysis of Furosemide and Spironolactone in bulk drug and their formulations.

Smart Spectrophotometric Methods for Concurrent Determination of Furosemide and Spironolactone Mixture in Their Pharmaceutical Dosage Forms

“…A comparative review has been carried out between the proposed methods, ratio difference (RD), ratio subtraction (RS), constant multiplication (CM) , absorbance subtraction (AS) and amplitude modulation (AM) and reported methods for this binary mixture, simultaneous equation and derivative ratio method DD (Millership, Parker, Donnelly, 2005;Chavan et al, 2018) indicating satisfactory results. RS and CM methods have a privilege over other univariate spectrophotometric reported methods for resolving the overlapping spectra that it regains D 0 absorption spectrum of each component in the mixture which acts as a spectral profile of each cited drug and uses its maxima for the determination and calculation of concentration.…”

“…Various methods were established for simultaneous analysis of FUR and SPR, including spectrophotometric methods (Millership, Parker, Donnelly, 2005;Israt et al, 2016;Chavan et al, 2018;Emam et al, 2018) and chromatographic methods (Maulik, Ketan, Shital, 2012;Ram, Dave, Joshi, 2012;Walash et al, 2012;Ram, Ram, Joshi, 2015;Naguib et al, 2018).…”

A Validated Simple, Rapid and Accurate RP-HPLC Approach for Measuring Vardenafil Hydrochloride Trihydrate in Bulk Drugs and Medicinal Formulations

“…The comprehensive evaluation of system suitability parameters is presented in Table 1, showcasing the robustness and reliability of the developed analytical system. [40][41][42][43][44][45] The remarkably low values of percent RSD for these parameters serve as compelling evidence of the system's exceptional reliability and consistency. Specifically, the mean peak area of 330575±0.4622, indicates excellent reproducibility, underscoring the system's ability to consistently measure the analyte's response.…”

Estimation of Furosemide Spectrophotometrically in Pharmaceutical preparations by Oxidative Coupling Reaction

“…Furosemide has potential interactions with these medications: Aspirin and other salicylates, other diuretics (e.g.ethacrynic acid, hydrochlorothiazide), Synergistic effects with other antihypertensives (e.g.doxazosin), and Sucralfate [6]. For the determination of furosemide, various analytical approaches have been used, spectrophotometry [7][8][9][10], HPLC [11][12][13][14], and other methods [15][16][17][18][19][20].…”